Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics:

Overview of the current JAK inhibitor landscape (0:00)
Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02)
Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17)
Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13)
Available clinical data with novel BET inhibitors (15:00)
Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50)
Emerging efficacy and safety findings reported with imetelstat for MF (18:57)
Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15)
Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05)
Other novel agents and strategies under investigation for MF (26:06)

Metaverse - Chancen, Risiken für Unternehmen